{"entity":{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","aka":["Cinrebafusp alfa (PRS-343)"],"tldr":"Cinrebafusp alfa is an experimental fusion protein from Pieris Pharmaceuticals in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.","summary":"Cinrebafusp alfa (PRS-343) is a fusion protein developed by Pieris Pharmaceuticals. Its target is HER2 (the sponsor names HER2 x 4-1BB). The sponsor states: Cinrebafusp alfa (PRS-343) is a HER2/4-1BB bispecific anticalin-antibody fusion protein that binds HER2 on tumour cells while engaging 4-1BB (CD137) to costimulate T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT05190445, plans to enrol 80 participants with primary completion was scheduled for 2023-02-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Cinrebafusp alfa","url":"https://clinicaltrials.gov/search?intr=PRS-343"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["her2","cd137"],"drugs":[],"companies":["pieris-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05190445"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PRS-343","modality":"fusion protein","mechanism":"Cinrebafusp alfa (PRS-343) is a HER2/4-1BB bispecific anticalin-antibody fusion protein that binds HER2 on tumour cells while engaging 4-1BB (CD137) to costimulate T cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cinrebafusp-alfa/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","route":"/companies/pieris-pharmaceuticals/"}],"trial":[{"id":"nct05190445","kind":"trial","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","route":"/trials/nct05190445/"}]}}